Search

Your search keyword '"Yap, Jeffrey T."' showing total 188 results

Search Constraints

Start Over You searched for: Author "Yap, Jeffrey T." Remove constraint Author: "Yap, Jeffrey T."
188 results on '"Yap, Jeffrey T."'

Search Results

2. Abstract 355: Examination of systemic myokine concentrations with risk of cachexia in non-metastatic colorectal cancer patients - Results from the ColoCare Study

3. Data from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

4. Supplementary Figure 7 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

5. Supplementary Figure Legends from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

6. Supplementary Figure 1 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

7. Supplementary Figure 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

8. Supplementary Table 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

9. Supplementary Table 2 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

10. Supplementary Figure 4 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

11. Supplementary Methods from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

12. Supplementary Table 1 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

13. Supplementary Figure 6 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

14. Supplementary Table 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

15. Supplementary Figure 5 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

16. Supplementary Figure 3 from Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

17. Prospective Pilot Study of 18F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas

21. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

22. Publisher Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

24. Abstract 3221: Differences in body composition among rectal cancer patients with neo-adjuvant treatment-related toxicity: Results from the ColoCare Study

26. Abstract A45: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

27. Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

29. Image reconstruction for dynamic PET based on low-order approximation and restoration of the sinogram

32. Contributors

35. Contributors

37. Lipopolysaccharide endotoxemia induces amyloid-β and p-tau formation in the rat brain

38. Abstract 2183: Protective autophagy elicited by RAF®MEK®ERK inhibition suggests a treatment strategy for pancreatic cancer

39. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers

40. The Influential Role of BCL2 Family Members in Synovial Sarcomagenesis

45. Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology

46. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer

48. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)

Catalog

Books, media, physical & digital resources